Our understanding of the clinical spectrum of myelin oligodendrocyte glycoprotein antibody-associated disease (MOG-AD) is in its infancy when compared to better studied central nervous system demyelinating diseases, such as multiple sclerosis (MS) and neuromyelitis optica spectrum disorder (NMOSD). This evidence concerns the gene MOG and multiple sclerosis.